Efungumab

From Wikipedia, the free encyclopedia

Efungumab?
Therapeutic monoclonal antibody
Source Human
Target Fungal Hsp90
Identifiers
CAS number  ?
ATC code  ?
PubChem  ?
Chemical data
Formula  ?
Mol. mass  ?
Pharmacokinetic data
Bioavailability Not applicable (IV only)
Protein binding High
Metabolism  ?
Half life 1–2 hours
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?
Legal status
Routes Intravenous

Efungumab (trade name Mycograb) is a human monoclonal antibody developed by NeuTec Pharma (a subsidiary of Novartis), intended to treat invasive Candida infection in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues.[1]

[edit] References

  1. ^ European Medicines Agency (2007). REFUSAL CHMP ASSESSMENT REPORT FOR MYCOGRAB. Procedure No. EMEA/H/C/658PDF (370 KiB). London: European Medicines Agency. Retrieved on 2007-11-20. Detailed assessment report with comprehensive overview of reasons for refusal of marketing authorization.
Pills  This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.
v • d • e
Human monoclonal antibodies ("-u-")
"-limu-" (immune system)
"-kinu-" (interleukin as target)
"-tumu-" (cancer immunotherapy)
"-osu-" (bone)
"-mulu-" (musculoskeletal)
"-fungu-" (fungal)
Efungumab
"-viru-" (viral)
"-bacu-" (bacterial)